Skip to content

Shattuck Labs

US · STTK #3662 by market cap Listed 2020
5.97 +0.31 +5.48%
Live - 5344 symbols - heartbeat 81s ago · 2026-10-09 19:30

Valuation each multiple against its own 5-year range

P/B ratio 2.69 Expensive vs history 76th percentile
5-year average 1.73 · #274 of 513 in Biotechnology
P/E ratio -12.85 Cheap vs history 4th percentile
5-year average -3.31 · forward -8.20
P/S ratio 567.55 Expensive vs history 94th percentile
5-year average 162.44 · forward 2,303.39 · #335 of 387 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Shattuck Labs (STTK) 599.17M -13.57 2.84 0.00%
Vertex Pharmaceuticals (VRTX) 129.29B 29.71 6.39 0.00%
Moderna (MRNA) 89.83B -28.20 13.29 0.00%
Regeneron Pharmaceuticals (REGN) 76.86B 18.47 2.42 0.49%
argenx SE (ARGX) 51.88B 31.43 6.16 0.00%
Revolution Medicines (RVMD) 40.67B -21.39 15.61 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value6.87 Economic moatNone UncertaintyVery High

Trading 15.1% below Morningstar's fair value estimate.

Fair value

Shattuck Labs Inc earns a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 18% discount to our quantitative fair value estimate of $6.87 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's balance sheet bolsters our estimated fair value. Low leverage mitigates financial risk, potentially boosting a firm's value. Reflecting the firm's leverage is its current ratio of 27.6, which sits in the top 10% globally. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which contributes to our view that shares are undervalued.

On a different note, the firm's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's sales yield, a core component of profitability, sits in the bottom 1% globally. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

Economic moat

The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-09 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Shattuck Labs discussion 0 comments

Add a comment